AVITA Medical to Host Investor Webinar Briefing on Q2 Earnings
ByAinvest
Monday, Aug 11, 2025 4:35 pm ET1min read
RCEL--
The webinar will cover AVITA Medical's Q2 2025 financial and business results, including its revenue growth and adjusted financial guidance. The company reported a 21.2% increase in total revenue to $18.42 million, driven by strong commercial sales. However, the company narrowed its net loss by 35.6% to $9.92 million, reflecting ongoing operational challenges [1].
Despite the revenue growth, AVITA Medical revised its full-year 2025 revenue guidance to a range of $76 million to $81 million, a 19% to 27% increase over 2024. This reduction was attributed to a 20% decline in RECELL demand during the first half of 2025 due to the reimbursement backlog [1].
The webinar will also discuss the company's strategic direction and product portfolio, which includes the FDA-approved RECELL System and Spray-On Skin Cells. The RECELL System harnesses the healing properties of a patient's own skin to create Spray-On Skin Cells, offering an innovative solution for improved clinical outcomes at the point-of-care [2].
Investors are encouraged to attend the webinar and submit their questions through the registration page. A replay will be available on AVITA Medical's investor relations website following the presentation [2].
References:
[1] https://www.ainvest.com/news/avita-medical-2025-q2-earnings-narrowed-losses-revenues-guidance-cut-2508/
[2] https://www.stocktitan.net/news/RCEL/avita-medical-to-host-investor-webinar-hhsoimnv4o5b.html
AVITA Medical will host an investor webinar on August 14, 2025, to discuss its second-quarter financial results. CEO Jim Corbett and CFO David O'Toole will present and answer questions. The webinar will be available for replay on the company's investor relations website. AVITA Medical specializes in acute wound care and has FDA-approved products like the RECELL System and Spray-On Skin Cells.
AVITA Medical (NASDAQ: RCEL), a leading therapeutic acute wound care company, will host an investor webinar on August 14, 2025, to discuss its second-quarter financial results. The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will provide insights into the company's performance and answer questions from investors [2].The webinar will cover AVITA Medical's Q2 2025 financial and business results, including its revenue growth and adjusted financial guidance. The company reported a 21.2% increase in total revenue to $18.42 million, driven by strong commercial sales. However, the company narrowed its net loss by 35.6% to $9.92 million, reflecting ongoing operational challenges [1].
Despite the revenue growth, AVITA Medical revised its full-year 2025 revenue guidance to a range of $76 million to $81 million, a 19% to 27% increase over 2024. This reduction was attributed to a 20% decline in RECELL demand during the first half of 2025 due to the reimbursement backlog [1].
The webinar will also discuss the company's strategic direction and product portfolio, which includes the FDA-approved RECELL System and Spray-On Skin Cells. The RECELL System harnesses the healing properties of a patient's own skin to create Spray-On Skin Cells, offering an innovative solution for improved clinical outcomes at the point-of-care [2].
Investors are encouraged to attend the webinar and submit their questions through the registration page. A replay will be available on AVITA Medical's investor relations website following the presentation [2].
References:
[1] https://www.ainvest.com/news/avita-medical-2025-q2-earnings-narrowed-losses-revenues-guidance-cut-2508/
[2] https://www.stocktitan.net/news/RCEL/avita-medical-to-host-investor-webinar-hhsoimnv4o5b.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet